I think we should not lose sight of the fact that the first two...

I think we should not lose sight of the fact that the first two cohorts are designed to show safety only. The first cohort is receiving a dose that is lower than the lowest given to any of the NHP's. The second cohort receives a dose equal to the lowest dose give to NHP's.

We should not get too caught up in unrealistic (hopeful) expectations that somehow efficacy or high transfection/transduction will be shown in these early cohorts. The other thing is that patients results will vary and no results from a single patient can be extrapolated as been indicative of a patient population.

The results were in-line with expectations and that is about all we should hope for at this stage in the game.